Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
← catalyst calendarNCT05397106 · readout in 889 d
Sponsored by Integra LifeSciences Corporation (industry) · IART — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
160actual
Sites
9
Countries
Belgium, Germany, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-24 | actual | When the study began enrolling |
| Primary completion | 2029-01-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-24 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hydrocephalus
- Hydrocephalus in Children
- NPH (Normal Pressure Hydrocephalus)
- IIH - Idiopathic Intracranial Hypertension
- Brain Tumor
- Post-Traumatic Hydrocephalus
- Hemorrhagic Stroke
Intervention
- Device: CODMAN CERTAS Plus Programmable Valve
Primary outcome
what the primary-completion date above is the date OFPrecise Device Placement: Maintaining Integrity and Functionality at 30 Days Post-Deployment
measured 30 Days
Permalink · IART's whole pipeline · Catalyst calendar · Every registered study · What changed